Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer

Sawaki,Masataka; Idota,Ai; Ichikawa,Mari; Gondo,Naomi; Horio,Akiyo; Kondo,Naoto; Hattori,Masaya; Fujita,Takashi; Yatabe,Yasushi; Iwata,Hiroji

doi:10.3892/ol.2014.2333

October 2014 Volume 8 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2014 Volume 8 Issue 4

Full Size Image

Article

Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer

Authors:
- Masataka Sawaki
- Ai Idota
- Mari Ichikawa
- Naomi Gondo
- Akiyo Horio
- Naoto Kondo
- Masaya Hattori
- Takashi Fujita
- Yasushi Yatabe
- Hiroji Iwata
View Affiliations / Copyright

Affiliations: Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi 464‑8681, Japan, Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Aichi 464‑8681, Japan
Pages: 1707-1712
|
Published online on: July 10, 2014

https://doi.org/10.3892/ol.2014.2333
Expand metrics +

Abstract

Axillary lymph node (LN) metastasis is one of the most important prognostic factors for the survival of breast cancer. The correlation between LN metastasis and the tumor (T) category has previously been investigated in certain case series. At present, the initial treatment approach is to define the intrinsic subtype, as it is significant in determining medical treatments, as well as being a prognostic factor. However, the intrinsic subtype is not known to predict the frequency of LN metastasis. The aim of the present study was to evaluate the frequency of LN metastasis with regard to tumor size according to the intrinsic subtype. In total, 654 patients with primary breast cancer were evaluated who underwent surgical resection between 2010 and 2011 at the Aichi Cancer Center Hospital (Nagoya, Aichi). The clinical and pathological data were analyzed for patients who underwent an axillary LN dissection or a sentinel LN biopsy for primary breast cancer. The intrinsic subtype of the primary tumors was classified using immunohistochemical staining of thin, paraffin‑embedded sections. In total, 157 (24.0%) of the 654 patients exhibited LN metastasis, and according to the primary tumor category, a larger tumor size was found to correlate with a higher proportion of LN positivity, as well as with the luminal A subtypes (n=364). In luminal B subtypes (n=110), T1a (n=2), T1b (n=12), T1c (n=55), T2 (n=34), and T3 (n=2) exhibited 50, 8.3, 38.2, 55.9 and 50% LN positivity, respectively. In luminal‑human epidermal growth factor receptor 2 (HER2) subtypes (n=46), T1c (n=17), T2 (n=10), and T3 (n=1) exhibited 40.1, 60 and 100% LN positivity, respectively. In HER2 subtypes (n=53), T1a (n=6), T1b (n=4), T1c (n=15), and T2 (n=10) exhibited 16.7, 25, 46.7 and 60% LN positivity, respectively. In triple‑negative subtypes (n=81), T1b (n=15), T1c (n=29), T2 (n=20), and T3 (n=2) exhibited 26.7, 24.1, 50 and 50% LN positivity, respectively. In conclusion, the intrinsic subtype is significant in predicting the frequency of LN metastasis with regard to tumor size.

View Figures

View References

1	Cancer Research UK. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/breast/. Accessed June 26, 2014
2	Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B and Senn HJ; Panel members. Strategies for subtypes - dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 22:1736–1747. 2011.
3	Cody HS III and Houssami N: Axillary management in breast cancer: what’s new for 2012? Breast. 21:411–415. 2012.
4	Silverstein MJ, Gierson ED, Waisman JR, Colburn WJ and Gamagami P: Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability. J Am Coll Surg. 180:700–704. 1995.
5	Sobin LH and Wittekind CH: Breast tumors. TNM Classification of Malignant Tumours. 6th edition. UICC, Wiley-Liss; New York, NY: pp. 131–142. 2002
6	Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 11:155–168. 1998.
7	Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.
8	Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 28:2784–2795. 2010.
9	Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007.
10	Penault-Llorca F, André F, Sagan C, et al: Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 27:2809–2815. 2009.
11	Dowsett M, Nielsen TO, A’Hern R, et al; International Ki-67 in Breast Cancer Working Group. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 103:1656–1664. 2011.
12	Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000.
13	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.
14	Arpino G, Generali D, Sapino A, et al: Gene expression profiling in breast cancer: a clinical perspective. Breast. 22:109–120. 2013.
15	Millikan RC, Newman B, Tse CK, et al: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat. 109:123–139. 2008.
16	Phipps AI, Buist DS, Malone KE, et al: Reproductive history and risk of three breast cancer subtypes defined by three biomarkers. Cancer Causes Control. 22:399–405. 2011.
17	Nguyen PL, Taghian AG, Katz MS, et al: Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 26:2373–2378. 2008.
18	Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009.
19	Morrison DH, Rahardja D, King E, Peng Y and Sarode VR: Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer. 107:382–387. 2012.
20	Yoshihara E, Smeets A, Laenen A, et al: Predictors of axillary lymph node metastases in early breast cancer and their applicability in clinical practice. Breast. 22:357–361. 2012.
21	Ravdin PM, De Laurentiis M, Vendely T and Clark GM: Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst. 86:1771–1775. 1994.
22	NCCN guideline 2013. ver2. 2013, http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed April 17, 2013

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Impact of intrinsic subtype on predicting axillary lymph node metastasis in breast cancer

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

Related Articles